U.S. pharmaceuticals company Eli Lilly plans to build a new plant in western Germany, sources close to the matter told Reuters, with one putting the investment at 2 bln euros

Eli Lily has the highest market capitalization of any Healthcare company, but its low revenue does not justify its lofty valuation at first glance. However, the company's average 5-year forward gro...

U.S. pharma company Eli Lilly plans to invest 2 billion euros ($2.17 billion) in a new plant in Alzey, western Germany, a source close to the negotiations told Reuters on Thursday.

A media report stated that the pharmaceutical giant intends to build a new factory in Germany. It will apparently fund the project entirely on its own.

U.S. pharma giant Eli Lilly plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a p...

Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly and Novo Nordisk amid growing demand for their product, securities fi...

Stock gains are great, but they don't necessarily continue forever. Today's fast rising investment can be tomorrow's disappointment.

For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that class of drugs for diabetes, a new survey shows.

'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.

'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.

CNBC's Jim Cramer on Monday emphasized his belief that companies making GLP-1 diabetes and obesity drugs will be valuable.

Novo Nordisk (NYSE:NVO) presented the full results from its SELECT cardiovascular trial at an American Heart Association (AHA) meeting on Saturday and analysts at Bank of America (BofA) Securities ...

Pharmaceutical giant Eli Lilly's experimental vaccine-like drug slashed a risk factor for heart disease by a whopping 94% for almost a year, according to a report.

Eli Lilly and Co (NYSE:LLY)'s experimental therapy lepodisiran reduced the harmful risk factor for lipoprotein (a) by up to 94% for up to a year with just a single dose, data from a first-in-human ...

Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse cardio...